Timothy A. Springer
CIK: 0001055624
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (69 total)
- Jun 9, 2026TECX
Tectonic Therapeutic, Inc.
Award(A)DirectStock Option (Right to Buy)
10.2K shares- - Jan 2, 2026RNAC
Cartesian Therapeutics, Inc.
Award(A)Direct2.6K shares- - Jun 9, 2025TECX
Tectonic Therapeutic, Inc.
Award(A)DirectStock Option (Right to Buy)
10.2K shares- - Apr 11, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Indirect53.7K shares at avg. $16.31$876K - Apr 11, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Direct9.5K shares at avg. $16.31$155K - Apr 11, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Indirect36.3K shares at avg. $10.77$391K - Apr 11, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct6.4K shares at avg. $10.77$69K - Apr 10, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Direct8.1K shares at avg. $16.73$135K - Apr 10, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Indirect45.9K shares at avg. $16.73$767K - Apr 10, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Indirect45.1K shares at avg. $10.43$471K - Apr 10, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct609 shares at avg. $10.92$7K - Apr 10, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct8K shares at avg. $10.43$83K - Apr 10, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Indirect3.5K shares at avg. $10.92$38K - Apr 9, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Indirect16.2K shares at avg. $14.62$237K - Apr 9, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Direct857 shares at avg. $15.23$13K - Apr 9, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Direct2.9K shares at avg. $14.62$42K - Apr 9, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Indirect4.9K shares at avg. $15.23$74K - Apr 9, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Indirect41.6K shares at avg. $9.43$392K - Apr 9, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct7.3K shares at avg. $9.43$69K - Apr 9, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Indirect178 shares at avg. $9.95$2K - Apr 9, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct31 shares at avg. $9.95$308.478 - Apr 7, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Indirect412.5K shares at avg. $17.10$7.1M - Apr 7, 2025TECX
Tectonic Therapeutic, Inc.
Purchase(P)Direct87.5K shares at avg. $17.10$1.5M - Mar 20, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct54.9K shares at avg. $15.59$856K - Mar 19, 2025RNAC
Cartesian Therapeutics, Inc.
Purchase(P)Direct20.2K shares at avg. $14.97$303K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 9, 2026 |  TECX Tectonic Therapeutic, Inc. | Award(A) Stock Option (Right to Buy) | 10,200 | - | - | Direct |
| Jan 2, 2026 |  RNAC Cartesian Therapeutics, Inc. | Award(A) | 2,600 | - | $0 | Direct |
| Jun 9, 2025 | TECX Tectonic Therapeutic, Inc. | Award(A) Stock Option (Right to Buy) | 10,200 | - | - | Direct |
| Apr 11, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 53,706 | $16.31 | $875,945 | Indirect |
| Apr 11, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 9,478 | $16.31 | $154,586 | Direct |
| Apr 11, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 36,338 | $10.77 | $391,455 | Indirect |
| Apr 11, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 6,412 | $10.77 | $69,074 | Direct |
| Apr 10, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 8,092 | $16.73 | $135,379 | Direct |
| Apr 10, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 45,858 | $16.73 | $767,204 | Indirect |
| Apr 10, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 45,144 | $10.43 | $471,055 | Indirect |
| Apr 10, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 609 | $10.92 | $6,652 | Direct |
| Apr 10, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 7,966 | $10.43 | $83,121 | Direct |
| Apr 10, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 3,451 | $10.92 | $37,696 | Indirect |
| Apr 9, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 16,215 | $14.62 | $237,063 | Indirect |
| Apr 9, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 857 | $15.23 | $13,052 | Direct |
| Apr 9, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 2,861 | $14.62 | $41,828 | Direct |
| Apr 9, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 4,856 | $15.23 | $73,957 | Indirect |
| Apr 9, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 41,604 | $9.43 | $392,176 | Indirect |
| Apr 9, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 7,342 | $9.43 | $69,209 | Direct |
| Apr 9, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 178 | $9.95 | $1,771 | Indirect |
| Apr 9, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 31 | $9.95 | $308 | Direct |
| Apr 7, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 412,500 | $17.10 | $7,053,750 | Indirect |
| Apr 7, 2025 | TECX Tectonic Therapeutic, Inc. | Purchase(P) | 87,500 | $17.10 | $1,496,250 | Direct |
| Mar 20, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 54,889 | $15.59 | $855,593 | Direct |
| Mar 19, 2025 | RNAC Cartesian Therapeutics, Inc. | Purchase(P) | 20,234 | $14.97 | $302,962 | Direct |
1-25 of 69 transactions
About SPRINGER TIMOTHY A
SPRINGER TIMOTHY A (SEC CIK 0001055624) files insider reports with the SEC as Director of Tectonic Therapeutic, Inc. (TECX) and Director of Cartesian Therapeutics, Inc. (RNAC).
Signal8 holds 16 ownership filings by SPRINGER TIMOTHY A, all Form 4s, filed between Sep 26, 2024 and Jun 10, 2026. Those filings report 69 transactions, from Sep 24, 2024 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SPRINGER TIMOTHY A's filings is in WATERTOWN, MA.
Recent filings by SPRINGER TIMOTHY A
- Jun 9, 2026: Grant or award of TECX derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of RNAC shares (Form 4, code A).
- Jun 9, 2025: Grant or award of TECX derivative securities (Form 4, code A).
- Apr 11, 2025: Open-market purchases of TECX shares (2 lines, Form 4, code P).
- Apr 11, 2025: Open-market purchases of RNAC shares (2 lines, Form 4, code P).
Other insiders filing for Tectonic Therapeutic, Inc. (TECX)
- REICIN ALISE, Chief Executive Officer
- Lochner Daniel, Chief Financial Officer
- McNamara Peter, Chief Scientific Officer
- Ruddy Marcella K., Chief Medical Officer
- Schwabish Marc, Chief Business Officer
- Tipirneni Praveen P., Director